Aardvark Therapeutics (AARD) Capital Expenditures (2024 - 2025)
Aardvark Therapeutics (AARD) posted Capital Expenditures of $4000.0 for Q3 2025, down 95.6% sequentially from $91000.0 in Q2 2025, and down 20.0% YoY from $5000.0 in Q3 2024.
Aardvark Therapeutics (AARD) Capital Expenditures (2024 - 2025) Analysis & Trends
Aardvark Therapeutics has reported Capital Expenditures for 2 years, with the latest figure at $4000.0 in Q3 2025.
- Quarterly Capital Expenditures fell 20.0% year-over-year to $4000.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $95000.0 (down 12.84% YoY) and the FY2025 annual result came in at $95000.0, down 12.84% from the prior year.
- Capital Expenditures fell to $4000.0 in Q3 2025 per AARD's latest filing, from $91000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $93000.0 in Q2 2024 and troughed at $4000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.94 Bn | 132.09 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.59 Bn | 78.60 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.67 Bn | 60.49 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.81 Bn | 52.67 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.41 Bn | 10.02 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 251.02 Mn |
| 10 | Aardvark Therapeutics | 140.91 Mn | 66.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 4,000.00 |
| Sep 30, 2025 | 4,000.00 |
| Jun 30, 2025 | 91,000.00 |
| Jun 30, 2025 | 91,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 93,000.00 |
| Jun 30, 2024 | 93,000.00 |
| Mar 31, 2024 | 5,000.00 |
| Mar 31, 2024 | 5,000.00 |